Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 721 citations

CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

Julia Kirchheiner, Kim Brøsen, Marja­‐Liisa Dahl et al. · Acta Psychiatrica Scandinavica · 2001 · 422 citations

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

Joyce A. Goldstein, Takashi Ishizaki, Kan Chiba et al. · Pharmacogenetics · 1997 · 352 citations

Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients

Ida Rudberg, B. Urbanczyk Mohebi, Monica Hermann et al. · Clinical Pharmacology & Therapeutics · 2007 · 231 citations

Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

Søren H. Sindrup, Kim Brøsen, M. G. J. Hansen et al. · Therapeutic Drug Monitoring · 1993 · 215 citations

Pharmacotherapy, Drug Resistance, Medicinal Chemistry +16